Get the Stockscreener App
0.00
100.00%
-5.84
Nevro Corp stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.
See More
Previous Close:
$5.84
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$221.21M
Revenue:
$425.17M
Net Income/Loss:
$-92.21M
P/E Ratio:
0.00
EPS:
-2.57
Net Cash Flow:
$-67.42M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$11.79
Nevro Corp Stock (NVRO) Company Profile
Name
Nevro Corp
Sector
Industry
Phone
650-251-0005
Address
1800 BRIDGE PARKWAY, REDWOOD CITY, CA
Compare NVRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVRO
Nevro Corp
|
0.00 | 221.21M | 425.17M | -92.21M | -67.42M | -2.57 |
|
ABT
Abbott Laboratories
|
128.85 | 225.27B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
101.90 | 138.41B | 17.55B | 2.03B | 2.37B | 1.37 |
|
SYK
Stryker Corp
|
365.06 | 129.62B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
84.16 | 107.92B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
76.04 | 40.53B | 5.54B | 4.18B | 259.90M | 7.00 |
Nevro Corp Stock (NVRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-10-25 | Upgrade | Jefferies | Underperform → Hold |
| Feb-07-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-03-24 | Initiated | Wells Fargo | Equal Weight |
| Dec-02-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Aug-09-24 | Upgrade | Citigroup | Sell → Neutral |
| Aug-08-24 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Aug-07-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Aug-07-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-07-24 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| May-22-24 | Downgrade | Citigroup | Neutral → Sell |
| Feb-22-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-21-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jul-19-23 | Initiated | Robert W. Baird | Neutral |
| May-31-23 | Initiated | RBC Capital Mkts | Outperform |
| May-15-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-14-23 | Initiated | Mizuho | Neutral |
| Jan-17-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-06-23 | Downgrade | Piper Sandler | Neutral → Underweight |
| Dec-20-22 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-12-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Underperform |
| May-05-22 | Upgrade | Citigroup | Neutral → Buy |
| Apr-13-22 | Resumed | Truist | Hold |
| Apr-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Underperform |
| Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-09-21 | Downgrade | Truist | Buy → Hold |
| Aug-05-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| Aug-05-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-05-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-05-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-05-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-09-21 | Downgrade | Redburn | Buy → Neutral |
| Jul-06-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-02-21 | Initiated | Piper Sandler | Overweight |
| Oct-23-20 | Initiated | Guggenheim | Buy |
| Sep-02-20 | Initiated | Robert W. Baird | Outperform |
| Jun-08-20 | Upgrade | UBS | Sell → Neutral |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jan-08-20 | Initiated | SunTrust | Buy |
| Jan-06-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-07-19 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-22-19 | Initiated | Oppenheimer | Perform |
| Mar-20-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Mar-20-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-28-18 | Initiated | UBS | Sell |
| Nov-07-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Nov-06-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-06-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Oct-19-18 | Downgrade | Goldman | Neutral → Sell |
| Jul-02-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-08-18 | Reiterated | Canaccord Genuity | Buy |
| May-08-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-08-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
View All
Nevro Corp Stock (NVRO) Latest News
Learn to Evaluate (NVRO) using the Charts - news.stocktradersdaily.com
Press Release Distribution & PR Platform - ACCESS Newswire
Nevro Receives CE Mark for Senza II™ Spinal Cord Stimulation System Delivering HF10™ Therapy | Libero Quotidiano.it - Libero Quotidiano
Nevro (NYSE:NVRO) Earns Hold Rating from Analysts at StockNews.com - Defense World
Levi & Korsinsky, LLP Investigates Nevro Corp. Data Breach - ACCESS Newswire
Form S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments - ADVFN
Prudential Financial Inc. Grows Position in Nevro Corp. (NYSE:NVRO) - MarketBeat
INVESTIGATION ALERT: Levi & Korsinsky, LLP Announces Investigation of Nevro Corp. Data Breach - ACCESS Newswire
Spinal Cord Stimulator Market to Set Phenomenal Growth From 2025 to 2034 | Medtronic,Boston Scientific,Nevro Corp - openPR.com
GMED Stock May Benefit Following the Acquisition of Nevro - MSN
Raymond James Financial Inc. Invests $287,000 in Nevro Corp. (NYSE:NVRO) - Defense World
Nevro (NYSE:NVRO) Coverage Initiated at StockNews.com - MarketBeat
DATA BREACH ALERT: Edelson Lechtzin LLP Is Investigating - GlobeNewswire
DATA BREACH ALERT: Edelson Lechtzin LLP Is Investigating Claims On Behalf Of Nevro Corp. Customers Whose Data May Have Been Compromised - TradingView
(NVRO) Trading Report - news.stocktradersdaily.com
Nevro Files Notice of Data Breach Affecting Confidential Consumer Information - JD Supra
Globus acquires US medical device company Nevro - Yahoo Finance
Globus Medical Completes Acquisition of Nevro Corp. - MyChesCo
Nevro Corp. Investigated by Federman & Sherwood for Data Breach - GlobeNewswire
Nevro to Participate in Wells Fargo 2022 MedTech R&D Spotlight Call Series - MarketScreener
Nevro Data Breach Investigation - Claim Depot
Nevro Corp Completes Merger and Delists from NYSE - TipRanks
Why Is Nevro (NVRO) Up 0.9% Since Last Earnings Report? - Yahoo Finance
Nevro Corp completes merger with Globus Medical - Investing.com Australia
Nevro Corp. Data Breach Exposes SSNs & Health Information - Claim Depot
Globus Medical Closes Acquisition of Nevro - MarketScreener
Globus Medical Acquires Nevro Corp. - citybiz
Globus Medical completes acquisition of Nevro - MassDevice
Globus Medical completes acquisition of Nevro Corp. - grafa.com
Nevro Corp completes merger with Globus Medical By Investing.com - Investing.com South Africa
SEC Form POS AM filed by Nevro Corp. - Quantisnow
Globus Medical completes acquisition of Nevro Corp. - Benzinga
Major Medical Tech Merger: Globus Medical's $2.5B Market Push Through Nevro Acquisition - Stock Titan
StockNews.com Initiates Coverage on Nevro (NYSE:NVRO) - MarketBeat
Here's Why you Should Retain Nevro Stock in Your Portfolio Now - MSN
Nevro Corp. (NYSE:NVRO) Receives Average Recommendation of "Reduce" from Brokerages - MarketBeat
Where are the Opportunities in (NVRO) - news.stocktradersdaily.com
Chronic Pain Associated with Painful Diabetic Neuropathy - openPR.com
SVP, Chief Operating Officer Christoforou Christofer was granted 852 shares and covered exercise/tax liability with 458 shares, increasing direct ownership by 0.32% to 123,588 units (SEC Form 4) - Quantisnow
SVP, Corp Dev and CLO Rashid Kashif was granted 1,136 shares and covered exercise/tax liability with 611 shares, increasing direct ownership by 0.38% to 140,462 units (SEC Form 4) - Quantisnow
SEC Form DEFA14A filed by Nevro Corp. - Quantisnow
NEVRO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nevro Corp.NVRO - Business Wire
Nevro Corp Stock (NVRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.01%
0.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):